Final answer:
The treatment of Rh alloimmunization, a condition that can lead to hemolytic disease of the newborn (HDN), focuses on early identification and the prevention of the mother's sensitization by administering RhoGAM during and after pregnancy.
Step-by-step explanation:
The treatment of Rh alloimmunization is aimed at early identification and intervention/prevention. This condition, also known as hemolytic disease of the newborn (HDN) or erythroblastosis fetalis, can occur when an Rh-negative mother is exposed to Rh-positive fetal red blood cells, leading to the production of anti-Rh antibodies. The primary intervention is the administration of Rho(D) immune globulin, commonly known as RhoGAM. This is given to the mother at around the 28th week of pregnancy and within 72 hours after delivery to prevent sensitization and the risk of HDN in subsequent pregnancies. The RhoGAM treatment targets and destroys fetal Rh-positive red blood cells in the mother's circulation before her immune system can react, thereby preventing the formation of anti-Rh antibodies.